News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharma, Ltd, a Subsidiary of Sucampo Pharmaceuticals, Inc., Announces Start of Phase 2b Study in Japan to Evaluate Lubiprostone for Chronic Idiopathic Constipation



11/29/2007 9:37:22 AM

TOKYO--(BUSINESS WIRE)--Sucampo Pharma Ltd. (SPL), a wholly-owned Japanese subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a specialty pharmaceutical company developing prostone-based therapies for age-related and other diseases, today announced the initiation of a multi-center Phase 2b dose-ranging study in Japan to evaluate the safety and efficacy of lubiprostone for adult Chronic Idiopathic Constipation.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES